Avisi Technologies is a clinical-stage medical device company committed to advancing vision care through innovative ophthalmic solutions. The company's portfolio includes state-of-the-art treatments for glaucoma and other ocular conditions. These include its flagship VisiPlate aqueous shunt, V-001 sustained intraocular drug-delivery platform, and the VisiPlate-S drainage device for treating mild to moderate glaucoma at the time of cataract surgery. Avisi has been recognized and supported by numerous organizations, including the National Science Foundation (NSF), the Glaucoma Research Foundation, SXSW, Johnson & Johnson JLABs, Medtech Innovator Accelerator, UCSF Rosenman Institute, and the University of Pennsylvania, among others.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
02/27/26	$10,700,000	Series A	Accanto Partners Golden Seeds Good Growth Capital Life Sciences Greenhouse MedVenture Partners OneOneFive Quaker Capital Investments SBI US Gateway Fund Sherpa Healthcare Partners SNBL	undisclosed